<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00530556</url>
  </required_header>
  <id_info>
    <org_study_id>L_8445</org_study_id>
    <nct_id>NCT00530556</nct_id>
  </id_info>
  <brief_title>Insomnia and Daytime Function in Osteoarthritis</brief_title>
  <official_title>Effect of Zolpidem vs Placebo on Insomnia and Daytime Function in Patients With Insomnia Associated With Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of zolpidem at doses up to 10 mg compared to placebo in&#xD;
      patients with insomnia associated with osteoarthritis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient's Global Impression of Therapy of Insomnia</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Insomnia,Sleep-related outcome measures from Morning Questionnaire, Daytime Functioning Life Event Questionnaire Pain Impact Questionnaire Use of rescue medications</measure>
  </secondary_outcome>
  <enrollment type="Actual">170</enrollment>
  <condition>Sleep Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolpidem</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients that are male or female aged 45 years or older.&#xD;
&#xD;
          -  Patients having given their written informed consent prior to participating in the&#xD;
             trial.&#xD;
&#xD;
          -  Patients who have had OA of the knee or hip for at least 6 months, as diagnosed using&#xD;
             the American College of Rheumatology Classification Criteria for Osteoarthritis.&#xD;
&#xD;
          -  Patients who, based on historical data, developed insomnia together with or after&#xD;
             development of arthritic symptoms and presently have difficulty in maintaining sleep&#xD;
             or have non-restorative sleep for at least three months preceding study entry and have&#xD;
             difficulties with daytime activities because of problems with sleeping.&#xD;
&#xD;
          -  Patients who, based on historical data, experience sleep disturbance at least 3 nights&#xD;
             per week.&#xD;
&#xD;
          -  Patients must have a score of greater than 1 on the Likert Pain Scale within two weeks&#xD;
             of study participation while taking pain medication&#xD;
&#xD;
          -  Patients must have been on a stable dosing regimen of analgesic/anti-inflammatory&#xD;
             medication for one month prior to study entry and agree to maintain the dose&#xD;
             throughout the study. Patient must agree not to exceed 4000 mg (i.e., 1000 mg&#xD;
             acetaminophen, 4 times per day) as rescue medication in case of unexpected arthritis&#xD;
             pain. Acetaminophen is the only rescue medication allowed in addition to the patient's&#xD;
             stable dosing regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients that are pregnant or are breast-feeding.&#xD;
&#xD;
          -  Patients with reproductive potential not implementing adequate contraceptive measures.&#xD;
&#xD;
          -  Patients with mental disorders or who cannot be relied upon to understand the trial&#xD;
             requirements and comply with the treatment regimen.&#xD;
&#xD;
          -  Patients that are shift workers or have required a change in their regular sleep&#xD;
             schedule by at least three hours within the last three months.&#xD;
&#xD;
          -  Patients that have been treated for insomnia within 2 years prior to the onset of&#xD;
             osteoarthritis.&#xD;
&#xD;
          -  Patients that have a history of recurrent major depressive disorder over the last 3&#xD;
             years or any single episode of major depression over the last 2 years.&#xD;
&#xD;
          -  Patients having a history of seizures or other significant neurological diseases.&#xD;
&#xD;
          -  Patients with a history of myasthenia gravis.&#xD;
&#xD;
          -  Patients that have had serious head injury within the past 10 years.&#xD;
&#xD;
          -  Patients with insulin dependent diabetes poorly controlled in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Patients who have had a stroke or myocardial infarction in the 6 months before the&#xD;
             screening visit.&#xD;
&#xD;
          -  Patients with unstable angina or severe heart failure.&#xD;
&#xD;
          -  Patients with a history of significant impairment of any organ system that could&#xD;
             impair the ability of the patient to participate in the study.&#xD;
&#xD;
          -  Patients with abnormal clinical laboratory tests judged by the Investigator to require&#xD;
             clinical intervention.&#xD;
&#xD;
          -  Patients that fail to complete at least 3 of 7 consecutive nights and days (day must&#xD;
             follow night to be consecutive) on their Evening and Morning Questionnaires during the&#xD;
             screening period and have not satisfied the following:&#xD;
&#xD;
               1. scored 2 or greater on the Evening Questionnaire, AND&#xD;
&#xD;
               2. Slept a total of less than 6 hours, as determined by:&#xD;
&#xD;
        a Wake Time after Sleep Onset of greater than 1 hour, and/or having time to fall asleep&#xD;
        (sleep latency) of 45 minutes or greater.&#xD;
&#xD;
          -  Patients that have used any drug (e.g. beta-blockers, antihistamines) and subsequently&#xD;
             reported significant CNS side effects.&#xD;
&#xD;
          -  Patients with a history of hypersensitivity/exaggerated drug response to&#xD;
             sedative/hypnotic drugs (allergic or paradoxical), including zolpidem.&#xD;
&#xD;
          -  Patients with a history of sleep apnea or current signs/symptoms associated with sleep&#xD;
             apnea&#xD;
&#xD;
          -  Patients with a history of symptoms compatible with diagnosis of periodic leg movement&#xD;
             or restless legs syndrome.&#xD;
&#xD;
          -  Patients with a history of cancer within the last 5 years or that have suspected&#xD;
             neoplastic disease (with the exception of nonmelanomatous skin cancer).&#xD;
&#xD;
          -  Patients that are taking any drugs of abuse or psychotropic drugs (including, but not&#xD;
             limited to antidepressants, antipsychotics, or anxiolytics) or drugs with demonstrated&#xD;
             effects on sleep-wake function (including, but not limited to herbal supplements,&#xD;
             diphenhydramine, and theophylline).&#xD;
&#xD;
          -  Patients that have used over-the-counter sleep medication within seven days prior to&#xD;
             study entry. Prescription sleep medications must have been discontinued at least 7-25&#xD;
             days prior to study entry, depending upon the half-life of the particular compound.&#xD;
&#xD;
          -  Patients who have taken investigational drugs within 30 days of the screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>September 14, 2007</study_first_submitted>
  <study_first_submitted_qc>September 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2007</study_first_posted>
  <last_update_submitted>February 15, 2012</last_update_submitted>
  <last_update_submitted_qc>February 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

